Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Tongbian granules (小儿通便颗粒) is a Class 1.1 innovative traditional Chinese medicine (TCM) developed by Jumpcan. Approved by China's National Medical Products Administration (NMPA) in August 2026, it is the first innovative TCM drug specifically approved for pediatric constipation under the new regulatory framework. The formula, which originates from a clinical prescription by pediatric expert Chen Yonghui of the Capital Center for Children's Health, Capital Medical University, is composed of herbal ingredients including Atractylodes macrocephala (白术), Citrus aurantium (枳壳), Magnolia officinalis (厚朴), and Raphanus sativus (莱菔子). It is indicated for the treatment of pediatric functional constipation with food accumulation syndrome, functioning to invigorate the spleen, regulate qi, promote digestion, and relieve constipation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiao'er Tongbian granules.